NEW YORK (GenomeWeb News) – Nanosphere today said that has signed an agreement with Eli Lilly to develop pharmacogenetic assays that Lilly will use in its drug development efforts.

The Northbrook, Ill.-based molecular diagnostics developer said that it would develop the assays to run on its new Verigene SP system, which is a sample-to-result, bench-top, molecular diagnostics instrument. It is a random access system that does not require PCR amplification, said Nanosphere.

Terms of the alliance have not been disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

Stat News reports that the head of IBM Watson Health is leaving her post.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.